Characteristic chromatogram establishment method and quality detection method of nerve-calming and mind-tranquilizing pill
A HPLC-based method for Anshen Dingzhi Pills identifies characteristic peaks under dual-wavelengths, addressing the lack of quality control, ensuring precise and reproducible quality evaluation.
Patent Information
- Application Number
- CN202411511995.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-28
- Publication Date
- 2024-12-06
AI Technical Summary
There is a lack of effective quality control methods for Anshen Dingzhi Pills, a traditional Chinese medicine composed of complex ingredients, which hinders its development and clinical application.
A method is established for Anshen Dingzhi Pills using high-performance liquid chromatography (HPLC) under dual-wavelength conditions to identify 14 characteristic peaks at 203nm and 9 peaks at 245nm, with specific pretreatment and gradient elution to separate and attribute peaks, ensuring reproducibility and accuracy.
The method provides a reliable quality control mechanism with high sensitivity and specificity, enabling precise quality evaluation and monitoring of Anshen Dingzhi Pills by identifying key components and reducing interference from impurities.
Smart Images

Figure CN119086783A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of Chinese medicine preparation component detection, and particularly relates to a characteristic spectrum establishment method and a quality detection method for Anshen Dingzhi Pills. Background Art
[0002] Anshen Dingzhi Pills, from the Qing Dynasty's Medical Enlightenment, are composed of Chinese medicines such as Poria, Poria, Ginseng, Polygala, Acorus tatarinowii, Dragon's Tooth, Cinnabar, and Honey. This prescription is simple but powerful. According to the basic theory of traditional Chinese medicine, its composition is analyzed. Anshen Dingzhi Pills are mainly composed of Poria, Poria, Polygala, and Ginseng to nourish the heart and calm the mind, supplemented by Acorus tatarinowii and Dragon's Tooth to calm the nerves and calm the mind. It has the effect of nourishing and descending, and Cinnabar is used to calm the nerves. The combination of these medicines can play the role of calming the mind and calming the mind, replenishing qi and calming the nerves. It is often used clinically for symptoms of heart and gallbladder qi deficiency and restlessness. Modern research shows that Anshen Dingzhi Pills have multiple pharmacological effects such as sedation and hypnosis, anticonvulsant, anti-anxiety, anti-depression, and anti-arrhythmia. Modern medical clinical research has found that Anshen Dingzhi Pills can effectively treat neurosis, but there is little research on the quality control of Anshen Dingzhi Pills.
[0003] Characteristic spectra are an important part of the quality control research of traditional Chinese medicine. By selecting some important characteristic information in the spectra as an important identification method for the quality control of traditional Chinese medicine, its internal quality uniformity and stability can be ensured. At present, the quality control technology of traditional Chinese medicine fingerprint spectrum has the advantages of convenient operation, rapidity and strong recognition ability. It is suitable for evaluating the quality characteristics of complex components of traditional Chinese medicine as a whole and has been increasingly widely used in the quality standard control of traditional Chinese medicine. However, there is no relevant report on the research of characteristic spectra of Anshen Dingzhi Pills.
[0004] Anshen Dingzhi Pills are composed of a variety of traditional Chinese medicines, and the ingredients are complex and difficult to control. Therefore, in order to promote the development of the classic formula of Anshen Dingzhi Pills and its quality control, it is urgent to establish the HPLC characteristic spectrum of Anshen Dingzhi Pills to provide a basis for the quality control and evaluation of Anshen Dingzhi Pills. Summary of the invention
[0005] In view of the above problems, the present invention provides a method for establishing a characteristic spectrum of Anshen Dingzhi Pills with high sensitivity, good specificity, accurate results and good reproducibility, and a quality detection method. Under the dual-wavelength conditions of liquid chromatography, a characteristic spectrum of Anshen Dingzhi Pills with 14 characteristic peaks under the wavelength of 203nm and 9 characteristic peaks under the wavelength of 245nm is finally obtained, and the characteristic peaks are located and attributed, and this method is applied to the quality detection of Anshen Dingzhi Pills.
[0006] The first object of the present invention is to provide a method for establishing a characteristic spectrum of Anshen Dingzhi Pills, comprising:
[0007] Preparation of the test solution of Anshen Dingzhi Pills: ultrasonic extraction of Anshen Dingzhi Pills, filtration, evaporation of the filtrate, re-dissolution with methanol, and filtration through a microporous membrane to prepare the test solution;
[0008] Polygala tenuifolia Ketone III, 3,6'-dicorinoylsucrose, ginsenoside Rb1, β-asarone and pachymic acid to prepare a reference solution;
[0009] Performing high performance liquid chromatography on multiple batches of test solution and reference solution respectively to obtain liquid chromatograms of the multiple batches of test solution and reference solution;
[0010] The liquid chromatograms of multiple batches of test solution and reference solution were compared and analyzed, and the common reference characteristic spectra of multiple batches of Anshen Dingzhi Pills were obtained;
[0011] The chromatographic peaks existing in the common control characteristic spectra of multiple batches of Anshen Dingzhi Pills were taken as common characteristic peaks, the relative retention times of the common characteristic peaks were determined, and the characteristic spectra of Anshen Dingzhi Pills were established.
[0012] Furthermore, the method of preparing multiple batches of test solution according to the formula of Anshen Dingzhi Pills includes:
[0013] After ultrasonic treatment of Anshen Dingzhi Pills in a water-saturated n-butanol solution, the solution was filtered, and the filtrate was evaporated to dryness. The solution was then re-dissolved with methanol and filtered through a microporous filter membrane to obtain a test solution of Anshen Dingzhi Pills.
[0014] Further, the dosage ratio of the Anshen Dingzhi Pills to the water-saturated n-butanol solution is 1g:15-50mL. For example, the dosage ratio of the Anshen Dingzhi Pills to the water-saturated n-butanol solution is 1g:15mL, 1g:16mL, 1g:17mL, 1g:18mL, 1g:19mL, 1g:20mL, 1g:21mL, 1g:21mL, 1g:22mL, 1g:23mL, 1g:24mL, 1g:25mL, 1g:26mL, 1g:27mL, 1g:28mL, 1g:29mL, 1g:30mL , 1g:31mL, 1g:32mL, 1g:33mL, 1g:34mL, 1g:35mL, 1g:36mL, 1g:37mL, 1g:38mL, 1g:39mL, 1g:40mL , 1g:41mL, 1g:42mL, 1g:43mL, 1g:44mL, 1g:45mL, 1g:46mL, 1g:47mL, 1g:48mL, 1g:49mL or 1g:50mL.
[0015] Preferably, the dosage ratio of the Anshen Dingzhi Pills to the water-saturated n-butanol solution is 1 g:25 mL.
[0016] Further, the ultrasonic treatment time is 20-40 min. For example, the ultrasonic treatment time is 20 min, 25 min, 30 min, 35 min or 40 min.
[0017] Preferably, in step (1), the ultrasonic treatment time is 30 min.
[0018] Further, the pore size of the filter membrane for filtration is 0.22-0.45 μm. For example, the pore size of the filter membrane for filtration is 0.22 μm or 0.45 μm.
[0019] Preferably, the pore size of the filter membrane is 0.22 μm.
[0020] The mass concentration of the test solution of the Shendingzhi Pills is 0.04 g / mL.
[0021] Furthermore, in the reference solution, The mass concentration of ketone III was 25-35 μg / mL, the mass concentration of 3,6'-dicercosylsucrose was 190-210 μg / mL, the mass concentration of ginsenoside Rb1 was 90-110 μg / mL, the mass concentration of β-asarone was 90-110 μg / mL and the mass concentration of pachymic acid was 35-45 μg / mL.
[0022] Preferably, in the reference solution, The mass concentration of ketone III was 30 μg / mL, the mass concentration of 3,6'-dicercosylsucrose was 200 μg / mL, the mass concentration of ginsenoside Rb1 was 100 μg / mL, the mass concentration of β-asarone was 100 μg / mL and the mass concentration of pachymic acid was 40 μg / mL.
[0023] Furthermore, in the high performance liquid chromatography detection, the detector is a DAD detector; the chromatographic column is a C18 chromatographic column; the detection temperature is 33-37°C; the injection volume is 5-20 μL; the flow rate of the mobile phase is 0.95-1.05 mL / min; the mobile phase is acetonitrile-phosphoric acid aqueous solution, wherein phase A is acetonitrile, phase B is phosphoric acid aqueous solution, and the volume percentage concentration of the phosphoric acid aqueous solution is 0.01-0.11%; the analysis time is 132 min; and gradient elution is used.
[0024] Illustratively, the detection temperature is 33°C, 34°C, 35°C, 36°C or 37°C.
[0025] Illustratively, the injection volume is 5 μL, 6 μL, 7 μL, 8 μL, 9 μL, 10 μL, 11 μL, 12 μL, 13 μL, 14 μL, 15 μL, 16 μL, 17 μL, 18 μL, 19 μL, or 20 μL.
[0026] Preferably, the injection volume is 10 μL.
[0027] Illustratively, the flow rate of the mobile phase is 0.95 mL / min, 0.96 mL / min, 0.97 mL / min, 0.98 mL / min, 0.99 mL / min, 1.00 mL / min, 1.01 mL / min, 1.02 mL / min, 1.03 mL / min, 1.04 mL / min, or 1.05 mL / min.
[0028] Preferably, the flow rate in the high performance liquid chromatography is 1.00 mL / min.
[0029] For example, the volume percentage concentration of the phosphoric acid aqueous solution is 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.10% or 0.11%.
[0030] Further, the gradient elution is:
[0031] 0-10min, the volume percentage of phase B is 95-85%, and the rest is phase A;
[0032] 10-13min, the volume percentage of phase B is 85%, and the rest is phase A;
[0033] 13-23min, the volume percentage of phase B is 85-84%, and the rest is phase A;
[0034] 23-35min, the volume percentage of phase B is 84-83%, and the rest is phase A;
[0035] 35-38min, the volume percentage of phase B is 83-78%, and the rest is phase A;
[0036] 38-46min, the volume percentage of phase B is 78-76%, and the rest is phase A;
[0037] 46-56min, the volume percentage of phase B is 76-72%, and the rest is phase A;
[0038] 56-63min, the volume percentage of phase B is 72-67%, and the rest is phase A;
[0039] 63-70min, the volume percentage of phase B is 67-60%, and the rest is phase A;
[0040] 70-89min, the volume percentage of phase B is 60%, and the rest is phase A;
[0041] 89-91min, the volume percentage of phase B is 60-52%, and the rest is phase A;
[0042] From 91 to 96 min, the volume percentage of phase B is 52-49%, and the rest is phase A;
[0043] 96-99min, the volume percentage of phase B is 49-23%, and the rest is phase A;
[0044] 99-111min, the volume percentage of phase B is 23-20%, and the rest is phase A;
[0045] 111-113min, the volume percentage of phase B is 20-16%, and the rest is phase A;
[0046] 113-125min, the volume percentage of phase B is 16%, and the rest is phase A;
[0047] 125-127min, the volume percentage of phase B is 16-95%, and the rest is phase A;
[0048] From 127 to 132 min, the volume percentage of phase B is 95%, and the rest is phase A.
[0049] Furthermore, in the HPLC detection, the detection wavelength is 203 nm and / or 245 nm.
[0050] Furthermore, in the high performance liquid chromatography detection, when the detection wavelength is 203 nm, the characteristic spectrum of Anshen Dingzhi Pills includes 14 common peaks, with peak 5 as the reference peak S, and a retention time of 1.0000, and the other 13 common peaks are arranged in ascending order of retention time as peak 1, peak 2, peak 3, peak 4, peak 6, peak 7, peak 8, peak 9, peak 10, peak 11, peak 12, peak 13, and peak 14. The retention times of peak 3 and peak 14 are 0.2771-0.3387, 0.2869-0.3507, 0.3779-0.4619, 0.4665-0.5701, 0.9347-1.1425, 1.0145-1.2400, 1.2982-1.5867, 1.4086-1.7216, 1.5525-1.8975, 1.7624-2.1540, 1.8270-2.2329, 2.5261-3.0875, and 2.6445-3.2321, respectively.
[0051] Furthermore, the peak No. 4 is Polygala tenuifolia The characteristic peak of ketone III, the peak No. 5 is the characteristic peak of 3,6'-diesinapoylsucrose, the peak No. 9 is the characteristic peak of ginsenoside Rb1, the peak No. 11 is the characteristic peak of β-asarone, and the peak No. 12 is the characteristic peak of pachymic acid.
[0052] Furthermore, in the high performance liquid chromatography detection, when the detection wavelength is 245 nm, the characteristic spectrum of Anshen Dingzhi Pills includes 9 common fingerprint peaks, with peak d as the reference peak S, and the retention time is 1.0000, and the other 8 common fingerprint peaks are arranged in ascending order of relative retention time as peak a, peak b, peak c, peak e, peak f, peak g, peak h, and peak i. The relative retention times of peak e, peak f, peak g, peak h and peak i are 0.2667-0.3260, 0.2760-0.3374, 0.3989-0.4875, 0.8664-1.0590, 0.9767-1.1937, 1.2498-1.5275, 1.3560-1.6573 and 1.6966-2.0736, respectively.
[0053] Furthermore, the peak No. d is a characteristic peak of 3,6'-diesinapoylsucrose.
[0054] Furthermore, when establishing the characteristic spectrum of Anshen Dingzhi Pills, the time window width used to match the common characteristic peaks is 0.1.
[0055] Preferably, the similarity of the common control characteristic spectrum of Anshen Dingzhi Pills measured in the present invention is ≥0.95.
[0056] The second object of the present invention is to provide a quality detection method for Anshen Dingzhi Pills, comprising:
[0057] Prepare the test sample solution of Anshen Dingzhi Pills to be tested;
[0058] The test solution is subjected to high performance liquid chromatography to obtain a liquid chromatogram of the Anshen Dingzhi Pills to be tested, wherein the conditions of the high performance liquid chromatography detection are the same as the above-mentioned high performance liquid chromatography detection conditions;
[0059] Compare the characteristic peaks and relative retention times of the liquid chromatogram of the Anshen Dingzhi Pills to be tested with the characteristic spectrum of the Anshen Dingzhi Pills established by the above method;
[0060] Based on the comparison of characteristic peaks and relative retention times, the quality test results of Anshen Dingzhi Pills to be tested are obtained.
[0061] Beneficial effects of the present invention:
[0062] The characteristic spectrum establishment method and quality detection method of Anshen Dingzhi Pills of the present invention have the following beneficial effects:
[0063] First, considering the complex chemical composition of Anshen Dingzhi Pills, a gradient elution method was used in the process of establishing the characteristic spectrum to solve the problem of difficulty in separating the characteristic peaks of Anshen Dingzhi Pills and interference from impurity peaks;
[0064] Second, the method provided by the present invention including the pretreatment method and the method for obtaining the chromatogram of Anshen Dingzhi Pills under specific liquid chromatography conditions was investigated by precision, stability and repeatability tests using relative retention time as an indicator, indicating that the method provided by the present invention has good adaptability, precision, stability and reproducibility;
[0065] Third, the fingerprint peaks in the characteristic spectrum of the Anshen Dingzhi Pills obtained by the present invention have a good sequence and mutual relationship, which is used as an overall feature to comprehensively characterize the effective ingredients in the Anshen Dingzhi Pills. Such a whole not only avoids the one-sidedness of judging the overall quality of the Anshen Dingzhi Pills by measuring only a small amount of ingredients, but also reduces the possibility of artificial processing for quality compliance. Further, it is used as a basis for evaluating the quality of the Anshen Dingzhi Pills sample to be tested;
[0066] Fourth, the present invention applies the above-mentioned method including the pretreatment method and the method of obtaining the chromatogram of Anshen Dingzhi Pills under specific liquid chromatography conditions to the quality detection of Anshen Dingzhi Pills, and uses the characteristic spectrum of Anshen Dingzhi Pills obtained as the evaluation basis, thereby realizing the quality monitoring of Anshen Dingzhi Pills.
[0067] Other features and advantages of the present invention will be described in the following description, and partly become apparent from the description, or understood by practicing the present invention. The purpose and other advantages of the present invention can be realized and obtained by the structures pointed out in the description, claims and drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0068] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0069] Figure 1 The common control characteristic spectra of the test solution and the reference solution of 16 batches of Anshen Dingzhi Pills in Example 1 of the present invention at a wavelength of 203 nm are shown;
[0070] Figure 2 The common control characteristic spectra of the test solution and the reference solution of 16 batches of Anshen Dingzhi Pills in Example 1 of the present invention at a wavelength of 245 nm are shown;
[0071] Figure 3 The characteristic spectrum of Anshen Dingzhi Pills at a wavelength of 203 nm according to Example 1 of the present invention is shown;
[0072] Figure 4 The characteristic spectrum of Anshen Dingzhi Pills at a wavelength of 245 nm according to Example 1 of the present invention is shown;
[0073] Figure 5 The superposition of the characteristic spectrum of the negative tasteless test solution and the standard characteristic spectrum of Anshen Dingzhi Pills at a wavelength of 203 nm in Example 2 of the present invention is shown;
[0074] Figure 6 The superposition of the characteristic spectrum of the negative tasteless test solution and the standard characteristic spectrum of Anshen Dingzhi Pills at a wavelength of 245 nm in Example 2 of the present invention is shown;
[0075] Figure 7 The superimposed characteristic spectra under different mobile phase conditions at a wavelength of 203 nm in Comparative Example 1 of the present invention are shown;
[0076] Figure 8 The superimposed characteristic spectra under different mobile phase conditions at a wavelength of 245 nm in Comparative Example 1 of the present invention are shown. DETAILED DESCRIPTION
[0077] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0078] The reagents and instruments used in the following examples are as follows:
[0079] Reagents
[0080] Methanol (OCEANPAK, chromatographic grade), acetonitrile (OCEANPAK, chromatographic grade), water was purified water (homemade), phosphoric acid (Shanghai Aladdin Biochemical Technology Co., Ltd., chromatographic grade), and other reagents were of analytical grade; Polygala tenuifolia Ketone III reference substance (China Food and Drug Inspection Institute, batch number: 111850-202207, purity 95.8%, for content determination); 3,6'-dienasosylsucrose reference substance (China Food and Drug Inspection Institute, batch number: 111848-202307, purity 96.7%, for content determination); β-asarone reference substance (China Food and Drug Inspection Institute, batch number: 112018-201802, purity 99.3%, for content determination); ginsenoside Rb1 (China Food and Drug Inspection Institute, batch number: 110704-202230, purity 95.1%, for content determination); Pachymic acid (Chengdu Pusi Biotechnology Co., Ltd., batch number: PS011922, purity 99.71%, complete infrared spectrum, ultraviolet spectrum, mass spectrum and nuclear magnetic spectrum for content determination).
[0081] instrument
[0082] Thermo Fisher U3000 chromatography system, including HPG-3400SD infusion pump, WPS-3000TSL ANALYTICAL autosampler, TCC-3000RS chromatography column oven, DAD-3000 UV detector; Thermo Fisher Vanqursh core chromatography system, including VC-P21-A infusion pump, VC-A13-A autosampler, VC-C10-A chromatography column oven, VC-D11-A UV detector; MS105DU / A (1 in 100,000, Mettler Toledo); ultrasonic instrument (Kunshan Jielimei Ultrasonic Instrument Co., Ltd.).
[0083] Example 1
[0084] The characteristic spectrum of Anshen Dingzhi Pills (abbreviated as ASDZW in the following data tables and sample labels) was established:
[0085] 1. Preparation of test solution:
[0086] Take 1 g of Anshen Dingzhi Pills reference sample, weigh it accurately, put it in a stoppered conical flask, accurately add 25 mL of water-saturated n-butanol solution, seal it, extract it with ultrasound for 30 min, shake it well, filter it, take the filtrate and evaporate it to dryness, add 5 mL of methanol to dissolve it, and filter it with a 0.22 μm microporous filter membrane to obtain the test solution.
[0087] 2. Preparation of reference solution:
[0088] Polygala tenuifolia Ketone III, 3,6'-dicornoylsucrose, ginsenoside Rb1, β-asarone, and pachymic acid reference substances were accurately weighed, dissolved in methanol solution and made up to volume, and diluted to prepare reference substance solutions with concentrations of 30μg / mL, 200μg / mL, 100μg / mL, 100μg / mL, and 40μg / mL, respectively.
[0089] 3. Determination
[0090] The test conditions of the high performance liquid chromatography method are as follows: the mobile phase is acetonitrile-0.05% phosphoric acid water, wherein phase A is acetonitrile and phase B is 0.05% phosphoric acid water; the flow rate is 1.0 mL / min; the detector is a DAD detector; the detection wavelengths are 203 nm and 245 nm; the chromatographic column is a C18 chromatographic column; the filler in the chromatographic column is octadecylsilane bonded silica gel; the column temperature is 35°C; the injection volume is 10 μL; the analysis time is 132 min; and the gradient elution is used.
[0091] Gradient elution, the specific procedure is:
[0092] 0-10min, the volume percentage of phase B is 95-85%, and the rest is phase A;
[0093] 10-13min, the volume percentage of phase B is 85%, and the rest is phase A;
[0094] 13-23min, the volume percentage of phase B is 85-84%, and the rest is phase A;
[0095] 23-35min, the volume percentage of phase B is 84-83%, and the rest is phase A;
[0096] 35-38min, the volume percentage of phase B is 83-78%, and the rest is phase A;
[0097] 38-46min, the volume percentage of phase B is 78-76%, and the rest is phase A;
[0098] 46-56min, the volume percentage of phase B is 76-72%, and the rest is phase A;
[0099] 56-63min, the volume percentage of phase B is 72-67%, and the rest is phase A;
[0100] 63-70min, the volume percentage of phase B is 67-60%, and the rest is phase A;
[0101] 70-89min, the volume percentage of phase B is 60%, and the rest is phase A;
[0102] 89-91min, the volume percentage of phase B is 60-52%, and the rest is phase A;
[0103] From 91 to 96 min, the volume percentage of phase B is 52-49%, and the rest is phase A;
[0104] 96-99min, the volume percentage of phase B is 49-23%, and the rest is phase A;
[0105] 99-111min, the volume percentage of phase B is 23-20%, and the rest is phase A;
[0106] 111-113min, the volume percentage of phase B is 20-16%, and the rest is phase A;
[0107] 113-125min, the volume percentage of phase B is 16%, and the rest is phase A;
[0108] 125-127min, the volume percentage of phase B is 16-95%, and the rest is phase A;
[0109] From 127 to 132 min, the volume percentage of phase B is 95%, and the rest is phase A.
[0110] 16 batches of test solution and reference solution of Anshen Dingzhi Pills were tested according to the above-mentioned HPLC test conditions to obtain chromatograms of the test solution and reference solution of 16 batches of Anshen Dingzhi Pills.
[0111] 4. Compare and analyze the chromatograms of the test solution and the reference solution of 16 batches of Anshen Dingzhi Pills obtained in the above steps:
[0112] The chromatograms of the test solution and the reference solution of the 16 batches of Anshen Dingzhi Pills obtained above were imported into the "2012 Edition of Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System" developed by the Chinese Pharmacopoeia Committee. The 01 batch of samples was used as the reference spectrum. The median method was used to generate the reference spectrum. The time window width of 0.1 was selected to match the common peaks of fingerprints, and the common reference characteristic spectrum of 16 batches of Anshen Dingzhi Pills was obtained.
[0113] The common reference characteristic spectra of 16 batches of Anshen Dingzhi Pills are shown in Figure 1 and Figure 2 , and ASDZW 01 The similarity of the comparison is shown in Table 1 and Table 2. Figure 1 This is the common reference characteristic spectrum of the test solution and reference solution of 16 batches of Anshen Dingzhi Pills at a wavelength of 203nm. Figure 2 These are the common control characteristic spectra of the test solutions and reference solutions of 16 batches of Anshen Dingzhi Pills at a wavelength of 245nm. Table 1 is the similarity at a wavelength of 203nm, and Table 2 is the similarity at a wavelength of 245nm.
[0114] Table 1 Similarity at 203nm wavelength
[0115]
[0116]
[0117]
[0118] Table 2 Similarity at 245nm wavelength
[0119]
[0120]
[0121] exist Figure 1 or Figure 2 The chromatographic peaks present in the samples were taken as common characteristic peaks, and 3,6'-dicerinoylsucrose was taken as reference peak S to determine the relative retention time of the common characteristic peaks. Figure 1 and Figure 2 , Figure 1 In the figure, S1 to S16 are 16 batches of Anshen Dingzhi Pills samples, R is the reference substance, and 14 is 14 common characteristic peaks; Figure 2 In the figure, S1~S16 are 16 batches of Anshen Dingzhi Pills samples, R is the reference substance, and 10 is 10 common characteristic peaks.
[0122] according to Figure 1 and Figure 2 The relative retention times of the common characteristic peaks were determined and the characteristic spectrum of Anshen Dingzhi Pills was constructed. Figure 3-Figure 4 , Figure 3 This is the characteristic spectrum of Anshen Dingzhi Pills at 203nm wavelength. Figure 4 This is the characteristic spectrum of Anshen Dingzhi Pills at a wavelength of 245nm.
[0123] like Figure 3 , 4 As shown in FIG. 1 , the characteristic spectrum of Anshen Dingzhi Pills includes a characteristic spectrum under 203 nm and a characteristic spectrum under 245 nm. Figure 3As shown in the figure, under the condition of 203nm, the characteristic spectrum of Anshen Dingzhi Pills contains 14 common fingerprint peaks, with peak 5 as the reference peak (S peak, retention time is 1.0000), and the other 13 common fingerprint peaks are arranged in ascending order according to relative retention time: peak 1 (relative retention time 0.2771-0.3387), peak 2 (relative retention time 0.2869-0.3507), peak 3 (relative retention time 0.3779 -0.4619), peak 4 (relative retention time 0.4665-0.5701), peak 6 (relative retention time 0.9347-1.1425), peak 7 (relative retention time 1.0145-1.2400), peak 8 (relative retention time 1.2982-1.5867), peak 9 (relative retention time 1.4086-1.7216), peak 10 (relative retention time 1.5525-1.8975), peak 11 (relative retention time 1.7624 -2.1540), peak 12 (relative retention time 1.8270-2.2329), peak 13 (relative retention time 2.5261-3.0875), peak 14 (relative retention time 2.6445-3.2321);
[0124] like Figure 4 As shown, the characteristic spectrum of Anshen Dingzhi Pills under 245nm conditions contains 8 common fingerprint peaks, with peak d as the reference peak (S peak, retention time of 1.0000), and the other 9 common fingerprint peaks are arranged in ascending order according to relative retention time: peak a (relative retention time 0.2667-0.3260), peak b (relative retention time 0.2760 -0.3374), peak c (relative retention time 0.3989-0.4875), peak e (relative retention time 0.8664-1.0590), peak f (relative retention time 0.9767-1.1937), peak h (relative retention time 1.2498-1.5275), peak i (relative retention time 1.3560-1.6573), and peak j (relative retention time 1.6966 -2.0736).
[0125] Example 2
[0126] Attribution and positioning of characteristic peaks in characteristic spectra:
[0127] 1. Remove any one of the medicinal materials from the Anshen Dingzhi Pills sample and prepare according to the steps of "Preparation of the Test Solution" in Example 1 to obtain a negative tasteless test solution;
[0128] 2. The negative tasteless test solution is subjected to high performance liquid chromatography to obtain a characteristic spectrum of the negative tasteless test solution, wherein the conditions of the high performance liquid chromatography detection are the same as those of the high performance liquid chromatography detection in Example 1;
[0129] 3. The characteristic spectrum of the negative tasteless test solution was compared with the characteristic spectrum of the Anshen Dingzhi Pills obtained in Example 1 (i.e. Figure 3 and Figure 4 ) were compared, and the common characteristic peaks of the corresponding single medicinal materials in the negative taste-deficient test solution in the standard characteristic spectrum of Anshen Dingzhi Pills were identified through relative retention time, so as to attribute and locate the characteristic peaks in the characteristic spectrum of the corresponding single medicinal materials in the negative taste-deficient test solution. The results are shown in Figure 5 and Figure 6 ,in, Figure 5 It is the superposition of the characteristic spectrum of the negative taste-deficient test solution and the standard characteristic spectrum of Anshen Dingzhi Pills at a wavelength of 203nm, among which S1~S8 are the negative test solution lacking Poria cocos, lacking Poria cocos, lacking ginseng, lacking Polygala tenuifolia, lacking Acorus calamus, lacking dragon tooth, lacking cinnabar, and lacking Poria cocos and Poria cocos, and S9 is the standard characteristic spectrum of Anshen Dingzhi Pills;
[0130] Figure 6 It is shown as the superposition of the characteristic spectrum of the negative taste-deficient test solution and the standard characteristic spectrum of Anshen Dingzhi Pills at a wavelength of 245nm, among which S1~S8 are the negative test solution lacking Poria cocos, lacking Poria cocos, lacking ginseng, lacking Polygala tenuifolia, lacking Acorus calamus, lacking Polygonum multiflorum, lacking Cinnabaris, and lacking Poria cocos and Poria cocos, and S9 is the standard characteristic spectrum of Anshen Dingzhi Pills.
[0131] pass Figure 5 and Figure 6 The characteristic peaks in the characteristic spectrum of Anshen Dingzhi Pills are located as follows: at a wavelength of 203nm, peaks 1, 2, 3, 4, 5, 6, 7, 8, 9, and 11 are derived from Polygala tenuifolia, peak 10 is derived from ginseng, peak 12 is derived from Acorus calamus and Polygala tenuifolia, peak 13 is derived from Poria cocos and Poria cocos; peak 14 is derived from ginseng, Acorus calamus and Polygala tenuifolia; at a wavelength of 245nm, peaks a, b, c, d, e, f, h, i, and j are all derived from Polygala tenuifolia.
[0132] Example 3
[0133] The method for establishing the characteristic spectrum of Anshen Dingzhi Pills provided by the present invention was methodologically verified, and the performance index results are as follows.
[0134] 1. Precision:
[0135] Take Anshen Dingzhi Pills sample, prepare the test solution according to the step of "Preparation of Test Solution" in Example 1, and analyze 6 times continuously according to the chromatographic conditions of HPLC detection in Example 1. Take 3,6'-dicerinoylsucrose as the reference peak, calculate the relative retention time of each peak, and the results are shown in Tables 3-4, wherein Table 3 is the relative retention time table at a wavelength of 203nm, and Table 4 is the relative retention time table at a wavelength of 245nm.
[0136] The data in Table 3 and Table 4 show that the RSD of the relative retention time of each characteristic peak is less than 1.0%, indicating that the instrument has good precision.
[0137] Table 3 Relative retention time table at 203nm wavelength
[0138]
[0139]
[0140] Table 4 Relative retention time table at 245nm wavelength
[0141]
[0142] 2. Repeatability
[0143] Take the same batch of Anshen Dingzhi Pills samples, and prepare 6 test solutions in parallel according to the step of "Preparation of Test Solution" in Example 1. According to the chromatographic conditions in the HPLC detection in Example 1, the samples were injected and analyzed respectively, and 3,6'-dicercosylsucrose was used as the reference peak to calculate the relative retention time of each peak. The specific results of repeatability are shown in Tables 5 and 6, wherein Table 5 is the relative retention time table at a wavelength of 203nm, and Table 6 is the relative retention time at a wavelength of 245nm.
[0144] The results in Table 5 and Table 6 show that the RSDs of the relative retention times are all less than 1.0%, indicating that the method has good repeatability.
[0145] Table 5 Relative retention time table at 203nm wavelength
[0146]
[0147]
[0148] Table 6 Relative retention time table at 245nm wavelength
[0149]
[0150] 3. Intermediate precision
[0151] Take Anshen Dingzhi Pills sample, prepare 6 test solutions according to the step of "Preparation of Test Solution" in Example 1, and calculate the relative retention time of each peak together with the repeatable fraction test sample according to the chromatographic conditions in the HPLC detection in Example 1, with 3,6'-dicerinoylsucrose as the reference peak. The results are shown in Tables 7 and 8, wherein Table 7 shows the relative retention time at different column temperatures under the condition of 203nm wavelength, and Table 8 shows the relative retention time at different column temperatures under the condition of 245nm wavelength.
[0152] The results in Tables 7 and 8 show that the RSDs of the relative retention times of the characteristic peaks were all less than 5.0%, indicating good intermediate precision.
[0153] Table 7 Relative retention time at different column temperatures at 203 nm wavelength
[0154]
[0155] Table 8 Relative retention time at different column temperatures at 245 nm wavelength
[0156]
[0157] 4. Durability
[0158] Take a sample of Anshen Dingzhi Pills, prepare a test solution according to the step of "Preparation of Test Solution" in Example 1, and use 3,6'-dierucyl sucrose as the reference peak according to the chromatographic conditions in the high performance liquid chromatography detection in Example 1. By slightly changing the flow rate, column temperature, and replacing different chromatographic columns, different instruments and other chromatographic condition parameters, the degree to which the determination results are not affected is investigated. The results are shown in Tables 9-16, wherein Table 9 is the relative retention time of different flow rates under the condition of 203nm wavelength, Table 10 is the relative retention time of different flow rates under the condition of 245nm wavelength, Table 11 is the relative retention time of different column temperatures under the condition of 203nm wavelength, Table 12 is the relative retention time of different column temperatures under the condition of 245nm wavelength, Table 13 is the relative retention time of different chromatographic columns under the condition of 203nm wavelength, Table 14 is the relative retention time of different chromatographic columns under the condition of 245nm wavelength, Table 15 is the relative retention time of different instruments under the condition of 203nm wavelength, and Table 16 is the relative retention time of different instruments under the condition of 245nm wavelength.
[0159] The results in Tables 9-16 show that the RSDs of the relative retention times of the various characteristic peaks were all less than 10.0%, indicating good durability.
[0160] Table 9 Relative retention time at different flow rates at 203 nm wavelength
[0161]
[0162] Table 10 Relative retention time at different flow rates at 245 nm wavelength
[0163]
[0164]
[0165] Table 11 Relative retention time at different column temperatures at 203 nm wavelength
[0166]
[0167] Table 12 Relative retention time at different column temperatures at 245 nm wavelength
[0168]
[0169]
[0170] Table 13 Relative retention time of different chromatographic columns at 203 nm wavelength
[0171]
[0172] Table 14 Relative retention time of different chromatographic columns at 245nm wavelength
[0173]
[0174] Table 15 Relative retention time of different instruments at 203nm wavelength
[0175]
[0176]
[0177] Table 16 Relative retention time of different instruments at 245nm wavelength
[0178]
[0179] Comparative Example 1
[0180] Chromatographic test of Anshen Dingzhi Pills:
[0181] Compared with the test method in Example 1, the difference is that acetonitrile-0.05% phosphoric acid water is replaced by methanol-0.05% phosphoric acid water during the detection process, and the rest is the same.
[0182] The characteristic spectrum of Anshen Dingzhi Pills is shown in Figure 7 and Figure 8 ,in, Figure 7 This is the superimposed characteristic spectrum of the ASDZW-01 sample under different mobile phase conditions at a wavelength of 203 nm, wherein S1 is acetonitrile-0.05% phosphoric acid water, S2 is methanol-0.05% phosphoric acid water, Figure 8 The superimposed characteristic spectra of the ASDZW-01 sample under different mobile phase conditions at a wavelength of 245 nm, where S1 is acetonitrile-0.05% phosphoric acid water and S2 is methanol-0.05% phosphoric acid water.
[0183] from Figure 7 and Figure 8It can be seen that the test solution was eluted with methanol-0.05% phosphoric acid water, with fewer chromatographic peaks and obvious fluctuations at a wavelength of 203 nm.
[0184] In summary, the characteristic spectrum establishment method of Anshen Dingzhi Pills provided in Example 1 can obtain a characteristic spectrum of Anshen Dingzhi Pills containing 14 characteristic peaks at a wavelength of 203nm and 9 characteristic peaks at a wavelength of 245nm, and locate and attribute the characteristic peaks, and the method has good precision, good repeatability, and good reproducibility, ensuring that the amount of effective ingredients in the components of Anshen Dingzhi Pills is relatively stable, thereby ensuring the safety and effectiveness of clinical medication. Therefore, the present invention overcomes various shortcomings in the prior art and has a high industrial utilization value.
[0185] Example 4
[0186] The quality inspection methods of Anshen Dingzhi Pills include:
[0187] 1. Prepare the Anshen Dingzhi Pills sample to be tested according to the step of "Preparation of Test Solution" in Example 1 to obtain the test solution of the Anshen Dingzhi Pills sample to be tested;
[0188] 2. The sample solution of the Anshen Dingzhi Pills to be tested is subjected to high performance liquid chromatography to obtain a liquid chromatogram of the Anshen Dingzhi Pills to be tested, wherein the conditions of the high performance liquid chromatography detection are the same as those of the high performance liquid chromatography detection in Example 1;
[0189] 3. Compare the liquid chromatogram of the Anshen Dingzhi Pills to be tested with Figure 3 and / or Figure 4 The characteristic peaks and relative retention times of the characteristic spectrum of Anshen Dingzhi Pills in the experiment were compared;
[0190] 4. Based on the comparison results of characteristic peaks and relative retention times, the quality results of the Anshen Dingzhi Pills to be tested are obtained, including:
[0191] If the characteristic peak comparison and relative retention time retention results show that the fingerprint peaks are fully covered and the similarity is greater than the threshold, it means that the quality of the Anshen Dingzhi Pills to be tested is qualified;
[0192] The threshold value is obtained by comparative analysis of the liquid chromatograms of qualified samples and unqualified samples, and the present invention does not specifically limit this value.
[0193] Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent substitutions for some of the technical features therein; and these modifications or substitutions do not make the essence of the corresponding technical solutions deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A method for establishing a characteristic spectrum of Anshen Dingzhi Pills, characterized in that: include: Prepare multiple batches of test solution according to the formula of Anshen Dingzhi Pills; Accurately weigh Polygala Ketone III, 3,6'-dicorinoylsucrose, ginsenoside Rb1, β-asarone and pachymic acid to prepare a reference solution; Performing high performance liquid chromatography on multiple batches of test solution and reference solution respectively to obtain liquid chromatograms of the multiple batches of test solution and reference solution; The liquid chromatograms of multiple batches of test solution were compared and analyzed with the liquid chromatograms of reference solution, and the common reference characteristic spectra of multiple batches of Anshen Dingzhi Pills were obtained; The chromatographic peaks existing in the common control characteristic spectra of multiple batches of Anshen Dingzhi Pills were taken as common characteristic peaks, the relative retention times of the common characteristic peaks were determined, and the characteristic spectra of Anshen Dingzhi Pills were established.
2. The method for establishing the characteristic spectrum of Anshen Dingzhi Pills according to claim 1, characterized in that: The method of preparing multiple batches of test solution according to the formula of Anshen Dingzhi Pills includes: After ultrasonic treatment of Anshen Dingzhi Pills in a water-saturated n-butanol solution, the solution was filtered, and the filtrate was evaporated to dryness. The solution was then re-dissolved with methanol and filtered through a microporous filter membrane to obtain a test solution of Anshen Dingzhi Pills.
3. The method for establishing the characteristic spectrum of Anshen Dingzhi Pills according to claim 2, characterized in that: The dosage ratio of the Anshen Dingzhi Pills to the water-saturated n-butanol solution is 1g:15-50mL; the ultrasonic treatment time is 20-40min; the pore size of the filtration membrane is 0.22-0.45μm; the mass concentration of the test solution of the Shendingzhi Pills is 0.1g / ml-0.3g / mL.
4. The method for establishing the characteristic spectrum of Anshen Dingzhi Pills according to claim 1, characterized in that: Polygala tenuifolia The mass concentration of ketone III was 25-35 μg / mL, the mass concentration of 3,6'-dicercosylsucrose was 190-210 μg / mL, the mass concentration of ginsenoside Rb1 was 90-110 μg / mL, the mass concentration of β-asarone was 90-110 μg / mL and the mass concentration of pachymic acid was 35-45 μg / mL.
5. The method for establishing the characteristic spectrum of Anshen Dingzhi Pills according to any one of claims 1 to 4, characterized in that: In the high performance liquid chromatography detection, the detector is a DAD detector; the chromatographic column is a C18 chromatographic column; the detection temperature is 33-37°C; the injection volume is 5-20 μL; the flow rate of the mobile phase is 0.95-1.05 mL / min; the mobile phase is acetonitrile-phosphoric acid aqueous solution, wherein phase A is acetonitrile, phase B is phosphoric acid aqueous solution, and the volume percentage concentration of the phosphoric acid aqueous solution is 0.01-0.11%; the analysis time is 132 min; and gradient elution is used.
6. The method for establishing the characteristic spectrum of Anshen Dingzhi Pills according to claim 5, characterized in that: The gradient elution is: 0-10min, the volume percentage of phase B is 95-85%, and the rest is phase A; 10-13min, the volume percentage of phase B is 85%, and the rest is phase A; 13-23min, the volume percentage of phase B is 85-84%, and the rest is phase A; 23-35min, the volume percentage of phase B is 84-83%, and the rest is phase A; 35-38min, the volume percentage of phase B is 83-78%, and the rest is phase A; 38-46min, the volume percentage of phase B is 78-76%, and the rest is phase A; 46-56min, the volume percentage of phase B is 76-72%, and the rest is phase A; 56-63min, the volume percentage of phase B is 72-67%, and the rest is phase A; 63-70min, the volume percentage of phase B is 67-60%, and the rest is phase A; 70-89min, the volume percentage of phase B is 60%, and the rest is phase A; 89-91min, the volume percentage of phase B is 60-52%, and the rest is phase A; From 91 to 96 min, the volume percentage of phase B is 52-49%, and the rest is phase A; 96-99min, the volume percentage of phase B is 49-23%, and the rest is phase A; 99-111min, the volume percentage of phase B is 23-20%, and the rest is phase A; 111-113min, the volume percentage of phase B is 20-16%, and the rest is phase A; 113-125min, the volume percentage of phase B is 16%, and the rest is phase A; 125-127min, the volume percentage of phase B is 16-95%, and the rest is phase A; From 127 to 132 min, the volume percentage of phase B is 95%, and the rest is phase A.
7. The method for establishing the characteristic spectrum of Anshen Dingzhi Pills according to claim 6, characterized in that: In the high performance liquid chromatography detection, the detection wavelength is 203 nm and / or 245 nm.
8. The method for establishing the characteristic spectrum of Anshen Dingzhi Pills according to claim 7, characterized in that: In the high performance liquid chromatography detection, when the detection wavelength is 203nm, the characteristic spectrum of Anshen Dingzhi Pills includes 14 common peaks, with peak 5 as the reference peak S peak, and the retention time is 1.0000, and the other 13 common peaks are arranged in ascending order of retention time as peak 1, peak 2, peak 3, peak 4, peak 6, peak 7, peak 8, peak 9, peak 10, peak 11, peak 12, peak 13, and peak 14, and the peaks 1, 2, 3, 4, 6, 7, 8, 9, 10, 11, 12, and 13 are The relative retention times of peak No. 14 are 0.2771-0.3387, 0.2869-0.3507, 0.3779-0.4619, 0.4665-0.5701, 0.9347-1.1425, 1.0145-1.2400, 1.2982-1.5867, 1.4086-1.7216, 1.5525-1.8975, 1.7624-2.1540, 1.8270-2.2329, 2.5261-3.0875, and 2.6445-3.2321.
9. The method for establishing the characteristic spectrum of Anshen Dingzhi Pills according to claim 8, characterized in that: The peak No. 4 is Polygala tenuifolia The characteristic peak of ketone III, the peak No. 5 is the characteristic peak of 3,6'-diesinapoylsucrose, the peak No. 9 is the characteristic peak of ginsenoside Rb1, the peak No. 11 is the characteristic peak of β-asarone, and the peak No. 12 is the characteristic peak of pachymic acid.
10. The method for establishing the characteristic spectrum of Anshen Dingzhi Pills according to claim 7, characterized in that: In the high performance liquid chromatography detection, when the detection wavelength is 245nm, the characteristic spectrum of Anshen Dingzhi Pills includes 9 common fingerprint peaks, with peak d as the reference peak S, and the retention time is 1.0000, and the other 8 common fingerprint peaks are arranged in ascending order of relative retention time as peak a, peak b, peak c, peak e, peak f, peak g, peak h, and peak i. The relative retention times of peak No. 1, peak No. 2, peak No. 3, peak No. 4, peak No. 5, peak No. 7, peak No. 8, peak No. 9, peak No. 10, peak No. 11, peak No. 12, peak No. 13, peak No. 14, peak No. 15, peak No. 17, peak No. 19, peak No. 21, peak No. 22, peak No. 24, peak No. 25, peak No. 26, peak No. 27 11. The method for establishing the characteristic spectrum of Anshen Dingzhi Pills according to claim 10, characterized in that: The peak No. d is the characteristic peak of 3,6'-diesinapoylsucrose.
12. A quality inspection method for Anshen Dingzhi Pills, characterized in that: include: Prepare the test sample solution of Anshen Dingzhi Pills to be tested; The test solution is subjected to high performance liquid chromatography to obtain a liquid chromatogram of the Anshen Dingzhi Pills to be tested, wherein the conditions of the high performance liquid chromatography detection are the same as the high performance liquid chromatography detection conditions in claim 1; Comparing the characteristic peaks and relative retention times of the liquid chromatogram of the Anshen Dingzhi Pill to be tested with the characteristic spectrum of the Anshen Dingzhi Pill according to any one of claims 1 to 11; Based on the comparison of characteristic peaks and relative retention times, the quality test results of Anshen Dingzhi Pills to be tested are obtained.
Citation Information
Patent Citations
Method for constructing HPLC characteristic spectra of kidney-tonifying nerve-calming drug
CN106442834A
Method for establishing fingerprint spectrum of granules for tranquilizing mind and tranquilizing mind
CN116298034A
Preparation method of kaixinsan powder
US20230181663A1
